Detailed Information on Publication Record
2018
Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management
ADÁMKOVÁ KRÁKOROVÁ, Dagmar, Katerina KUBACKOVA, Ladislav DUŠEK, Tomáš TOMÁŠ, Pavel JANÍČEK et. al.Basic information
Original name
Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management
Authors
ADÁMKOVÁ KRÁKOROVÁ, Dagmar (203 Czech Republic), Katerina KUBACKOVA (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Tomáš TOMÁŠ (203 Czech Republic), Pavel JANÍČEK (203 Czech Republic), Štěpán TUČEK (203 Czech Republic), Jana PRAUSOVA (203 Czech Republic), Igor KISS (203 Czech Republic) and Iva ZAMBO (203 Czech Republic, guarantor)
Edition
PATHOLOGY & ONCOLOGY RESEARCH, DORDRECHT, SPRINGER, 2018, 1219-4956
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30109 Pathology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.433
RIV identification code
RIV/00216224:14110/18:00103942
Organization unit
Faculty of Medicine
UT WoS
000433372000023
Keywords in English
Ewing sarcoma; Adults; Multimodal treatment; Risk factors; Prognosis
Tags
International impact, Reviewed
Změněno: 9/2/2019 20:07, Soňa Böhmová
Abstract
V originále
Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.